353 related articles for article (PubMed ID: 17409398)
21. Advances in the development of siRNA-based therapeutics for cancer.
Shen Y
IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.
Yano J; Hirabayashi K; Nakagawa S; Yamaguchi T; Nogawa M; Kashimori I; Naito H; Kitagawa H; Ishiyama K; Ohgi T; Irimura T
Clin Cancer Res; 2004 Nov; 10(22):7721-6. PubMed ID: 15570006
[TBL] [Abstract][Full Text] [Related]
23. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy.
Subramaniam V; Vincent IR; Gilakjan M; Jothy S
Exp Mol Pathol; 2007 Dec; 83(3):332-40. PubMed ID: 17945212
[TBL] [Abstract][Full Text] [Related]
24. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
25. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.
Griesenbach U; Kitson C; Escudero Garcia S; Farley R; Singh C; Somerton L; Painter H; Smith RL; Gill DR; Hyde SC; Chow YH; Hu J; Gray M; Edbrooke M; Ogilvie V; MacGregor G; Scheule RK; Cheng SH; Caplen NJ; Alton EW
Respir Res; 2006 Feb; 7(1):26. PubMed ID: 16480492
[TBL] [Abstract][Full Text] [Related]
26. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.
Hogrefe RI; Lebedev AV; Zon G; Pirollo KF; Rait A; Zhou Q; Yu W; Chang EH
Nucleosides Nucleotides Nucleic Acids; 2006; 25(8):889-907. PubMed ID: 16901821
[TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model.
Podesta JE; Al-Jamal KT; Herrero MA; Tian B; Ali-Boucetta H; Hegde V; Bianco A; Prato M; Kostarelos K
Small; 2009 May; 5(10):1176-85. PubMed ID: 19306454
[TBL] [Abstract][Full Text] [Related]
29. Bacterial delivery of siRNAs: a new approach to solid tumor therapy.
Xu DQ; Zhang L; Kopecko DJ; Gao L; Shao Y; Guo B; Zhao L
Methods Mol Biol; 2009; 487():161-87. PubMed ID: 19301647
[TBL] [Abstract][Full Text] [Related]
30. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
[TBL] [Abstract][Full Text] [Related]
31. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
Choi YS; Lee JY; Suh JS; Kwon YM; Lee SJ; Chung JK; Lee DS; Yang VC; Chung CP; Park YJ
Biomaterials; 2010 Feb; 31(6):1429-43. PubMed ID: 19954842
[TBL] [Abstract][Full Text] [Related]
32. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition.
Yoo JY; Kim JH; Kim J; Huang JH; Zhang SN; Kang YA; Kim H; Yun CO
Gene Ther; 2008 May; 15(9):635-51. PubMed ID: 18273054
[TBL] [Abstract][Full Text] [Related]
33. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo.
Minakuchi Y; Takeshita F; Kosaka N; Sasaki H; Yamamoto Y; Kouno M; Honma K; Nagahara S; Hanai K; Sano A; Kato T; Terada M; Ochiya T
Nucleic Acids Res; 2004 Jul; 32(13):e109. PubMed ID: 15272050
[TBL] [Abstract][Full Text] [Related]
34. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].
Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J
Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742
[TBL] [Abstract][Full Text] [Related]
35. [Activation of multiple tumor suppressor genes by MBD1 siRNA in pancreatic cancer cell line BxPC-3].
Xu J; Liu C; Yu XJ; Jin C; Fu DL; Ni QX
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1948-51. PubMed ID: 19062732
[TBL] [Abstract][Full Text] [Related]
36. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
37. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy.
Kim WJ; Chang CW; Lee M; Kim SW
J Control Release; 2007 Apr; 118(3):357-63. PubMed ID: 17313987
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf.
Nakai N; Kishida T; Shin-Ya M; Imanishi J; Ueda Y; Kishimoto S; Mazda O
Gene Ther; 2007 Feb; 14(4):357-65. PubMed ID: 17024102
[TBL] [Abstract][Full Text] [Related]
39. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
40. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
